Merck Raises Zocor Projections For 2005 Due To Less Than Expected Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck believes Zocor (simvastatin) will perform better than initially projected in 2005 based mostly on less than expected competition in the market